Navigation Links
Webcast Alert: Isis Pharmaceuticals' 2010 Financial Results and Highlights Conference Call
Date:2/14/2011

CARLSBAD, Calif., Feb. 14, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:What:

Isis Pharmaceuticals' 2010 Financial Results and HighlightsWhen:

Monday, February 28, 2011 at 4:30 p.m. ET / 1:30 p.m. PTWhere:

www.isispharm.comHow:

Live on the Internet.  Simply log onto our Web site listed above. If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 24 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis has designed and executed a patent strategy that has provided the Company with strong and extensive protection for Isis' drugs as well as all aspects of antisense drug discovery, development and manufacturing.  Additional information about Isis is available at www.isispharm.com.


'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Talecris Biotherapeutics Announces Teleconference and Webcast Information for Special Meeting of Shareholders
2. Sangamo BioSciences Announces Fourth Quarter and Full Year 2010 Conference Call and Webcast
3. Amgen Announces Webcast of 2010 Fourth Quarter and Full Year Financial Results
4. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2010 Earnings Conference Call
5. Regenicin CEO to Participate in Live Webcast at OneMedForum Business Development and Finance Conference, January 11th at 4:00 PM PST
6. Gen-Probe to Webcast Presentation at the 29th Annual J.P. Morgan Healthcare Conference
7. Gentiva® Health Services Schedules 2011 Outlook Conference Call and Webcast for Thursday, December 16, 2010
8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2011 Results; Teleconference and Webcast to be held on November 16, 2010
9. Resverlogix Notice of Conference Call & Webcast to Discuss ASSERT Clinical Trial Data
10. Palatin Technologies, Inc. to Report Fiscal Year 2011 First Quarter Results; Teleconference and Webcast to be Held on November 16, 2010
11. Hikma Expands its Global Injectables Business - Live Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014   MSC , a ... safety, today announced the appointment of Mary Beth ... With 28 years of experience preparing companies for rapid ... as Executive Vice President of Corporate Development and Healthcare. ... improvement business , as well as corporate strategy and ...
(Date:8/27/2014)... 27, 2014 The Global and China ... on the current state of the Trifluoroacetic Acid industry ... basic overview of the industry, including definitions, applications and ... market analysis are provided with a focus on history, ... comparison between the international and Chinese situation is also ...
(Date:8/27/2014)... Aug. 27, 2014 Research and ... "Global Lactic Acid  (Biodegradable Polymer, Food & Beverage, ... Forecasts to 2019" report to their offering. ... acid with an asymmetrical carbon atom. The main ... polymer, food and beverage, personal care product, and ...
(Date:8/27/2014)... , Aug. 27, 2014  A novel biomarker ... help physicians better identify early-stage disease, when treatment ... according to a new study in The Journal ... (NYSE: DGX ) and other institutions ... protein outperformed conventional antibody-serum testing, including rheumatoid factor ...
Breaking Biology Technology:MSC names Mary Beth Loesch President and CEO 2Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4
... Hailed as a "cross between a high-speed centrifuge ... developed a new, practical technology for fabricating tiny nanofibers. ... to the fairground treat of spun sugar is deliberate, ... pushes out 100 nanometer-diameter polymer-based threads using a rotating ...
... Shire plc (LSE: SHP, Nasdaq: ... results of a study evaluating the safety and efficacy of ... of Attention Deficit Hyperactivity Disorder ( ADHD ) in adolescents ... oral session at a national scientific meeting of psychiatrists in ...
... fishery is misleading , , , ... 25 The Pew Environment Group today criticized the decision by the Marine ... the entire fishery for Antarctic krill is sustainable when in reality it is not. ... Seafood with the MSC label implies that ...
Cached Biology Technology:Inspired by a cotton candy machine, engineers put a new spin on creating tiny nanofibers 2Inspired by a cotton candy machine, engineers put a new spin on creating tiny nanofibers 3Study Evaluated Vyvanse® (lisdexamfetamine dimesylate) Capsules CII Efficacy and Safety in Adolescents with ADHD 2Study Evaluated Vyvanse® (lisdexamfetamine dimesylate) Capsules CII Efficacy and Safety in Adolescents with ADHD 3Study Evaluated Vyvanse® (lisdexamfetamine dimesylate) Capsules CII Efficacy and Safety in Adolescents with ADHD 4Study Evaluated Vyvanse® (lisdexamfetamine dimesylate) Capsules CII Efficacy and Safety in Adolescents with ADHD 5Study Evaluated Vyvanse® (lisdexamfetamine dimesylate) Capsules CII Efficacy and Safety in Adolescents with ADHD 6Study Evaluated Vyvanse® (lisdexamfetamine dimesylate) Capsules CII Efficacy and Safety in Adolescents with ADHD 7Study Evaluated Vyvanse® (lisdexamfetamine dimesylate) Capsules CII Efficacy and Safety in Adolescents with ADHD 8Pew Faults Marine Stewardship Council's Decision 2Pew Faults Marine Stewardship Council's Decision 3
(Date:8/28/2014)... 28, 2014) Researchers at the University of Minnesota ... dystrophy (FSHD) to be used for muscle regeneration research ... therapies for FSHD. , The research is published in ... . , There is no treatment for FSHD, which ... type of muscular dystrophy. FSHD is an unusual genetic ...
(Date:8/28/2014)... The support of peer groups and clinicians is ... according to recent University of Georgia research. , ... Athens-Clarke County area determined that role models for ... mothers of infants. , "Mothers who received that ... breastfeeding," said study co-author Alex Anderson, an associate ...
(Date:8/28/2014)... Advocate and Senior Staff Attorney at the Electronic Frontier ... of biometric and mobile commerce experts set to speak ... Tampa, Florida on September 15, ... Rahman, Director, Technology and Strategy at Samsung, and Philippe de ... this year,s event is Mobility at the Crossroads of ...
Breaking Biology News(10 mins):UMN researchers find animal model for understudied type of muscular dystrophy 2Breastfeeding study shows need for effective peer counseling programs 2Biometrics UnPlugged Welcomes the Electronic Frontier Foundation's Jennifer Lynch to the Mobility at the Crossroads of Commerce and Privacy Summit 2
... Allen Institute for Brain Science announced today that ... to develop and manufacture a state-of-the-art sensor array ... Allen Institute for Brain Science in partnership with ... Charitable Foundation, the Wellcome Trust and University College ...
... Germany , November 7, 2013 ... Trade Prize to the biometrics company DERMALOG for its ... worldwide export of its groundbreaking fingerprint technology. ... against unauthorised access is a very important issue in ...
... Philadelphia, PA, November 7, 2013 The knowledge and skills ... are often unavailable to those living with financial limitations. ... to their achieving better diets. However, two researchers ... that looked at the effects that three educational sessions ...
Cached Biology News:Allen Institute for Brain Science partners with imec for development of next-generation tools 2Biometrics Pioneer DERMALOG Awarded German Foreign Trade Prize 23 'hands on' nutrition classes -- Enough to impact health behaviors in lower income women 2
... an automated hybridization system for the processing ... the hybridization and post hybridization washing of ... instrument can process up to 12 slides ... multi-protocol software, enabling the user to run ...
a1-Antitrypsin (human, alpha-1 AT)...
C1-inhibitor (C1-INH)...
Glucagon-like peptide-1 (GLP-1 (1-36) amide)...
Biology Products: